In summary, our data confirm that while the new hyperekplexia variant is a loss of function regarding GlyT2 activity, it may gain the function of altering proteostasis through triggering the UPR and probably interfering with lipid raft-dependent processes. The gene discussed is SLC6A5; the disease is hyperekplexia.